KLRC1 and neoplasm: Finally, targeting the inhibitory receptor NKG2A may be of interest, since this molecule is expressed on tumor-infiltrating NKG2A+ CD8+ TRM cells and the blockade of NKG2A potentiates CD8+ T cell immunity when combined with cancer vaccines and PD-1 blockade [99,100].